937402-51-2
Chemical Structure
ODN 1018
Synonym(s): 1018 ISS
- CAS No.: 937402-51-2
- Formula:N/A
- Molecular Weight:7150.00
IUPAC Name: 5,13-bis(4-((1-(3-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methoxy)phenoxy)-6,12-bis(4-((1-(3-((2S,3S,4S,5R)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methoxy)phenoxy)-2-((1-(3-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)-9-((1-(3-((2S,3S,4S,5R)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)anthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-1,3,8,10(2H,9H)-tetraone
SMILES: [DNA, d(P-thio)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)]
Biological Activity: ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ODN 1018 | 99.28% | ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang X, et al. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature. 2025;641(8061):202-210. [Content Brief]
- [2]. Campbell JD, et al. A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice. Thorax. 2014;69(6):565-573. [Content Brief]
- [3]. Barrat FJ, et al. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008;223:271-283. [Content Brief]
Keywords
